Literature DB >> 17488295

Antibodies against oxidized phospholipids in laboratory tests exploring lupus anti-coagulant activity.

R Rolla1, M Vidali, R Serino, P Pergolini, E Albano, G Bellomo.   

Abstract

Lupus anti-coagulants (LA) are a variety of anti-phospholipid antibodies characterized by their capacity to interfere with phospholipid-dependent coagulation assays. LA are increasingly recognized as important predictors of thrombosis. However, the antigen specificity of LA is still poorly characterized. Growing evidence indicates that oxidized phospholipids are among the targets of anti-phospholipid antibodies. This prompted us to investigate the role of IgG directed against different oxidized phospholipids in 164 subjects without clotting factor defects that were tested for the presence of LA using a LA-sensitive activate partial thromboplastin time (aPTT-FSL) and a screening/confirmation assay based on diluted Russell's viper venom test (dRVVT-PL). The response to aPTT-FSL was significantly (P < 0.0005) associated with high titres of IgG against oxidized phosphatidylserine, phosphatidylethanolamine and phosphatidylinositol, whereas positivity to dRVVT-PL was associated with the elevation of IgG against oxidized phosphatidylserine, phosphatidylcholine, phosphatidylethanolamine (P < 0.0005) and phosphatidylinositol (P < 0.01). No difference in reactivity against oxidized cardiolipin was evident between the different groups. Positivity to the dRVVT-PL test was also associated significantly (P < 0.005) with the elevation of anti-cardiolipin and anti-beta(2)-glycoprotein-1 IgG. However, stepwise logistic regression demonstrated that IgG recognizing oxidized phosphatidylethanolamine and oxidized phosphatidylcholine were the only independent predictors of the response to dRVVT-PL assay, while IgG recognizing oxidized phosphatidylethanolamine and oxidized phosphatidylinositol were independent predictors of the response to aPTT-FSL test. In conclusion, autoantibodies against defined oxidized phospholipids are independent predictors of LA detection by aPTT-FSL or dRVVT-PL assays and might contribute to the variability often observed in the responses to the functional tests detecting LA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17488295      PMCID: PMC1942029          DOI: 10.1111/j.1365-2249.2007.03404.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  32 in total

Review 1.  Antiphospholipid antibodies and thrombosis.

Authors:  M Greaves
Journal:  Lancet       Date:  1999-04-17       Impact factor: 79.321

Review 2.  The antiphospholipid syndrome.

Authors:  Jerrold S Levine; D Ware Branch; Joyce Rauch
Journal:  N Engl J Med       Date:  2002-03-07       Impact factor: 91.245

Review 3.  Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature.

Authors:  Monica Galli; Davide Luciani; Guido Bertolini; Tiziano Barbui
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

Review 4.  Molecular pathogenesis of the antiphospholipid syndrome.

Authors:  Jacob H Rand
Journal:  Circ Res       Date:  2002-01-11       Impact factor: 17.367

5.  Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant.

Authors:  T Atsumi; M Ieko; M L Bertolaccini; K Ichikawa; A Tsutsumi; E Matsuura; T Koike
Journal:  Arthritis Rheum       Date:  2000-09

6.  Effect of cardiolipin oxidation on solid-phase immunoassay for antiphospholipid antibodies.

Authors:  M Schlame; I Haller; L R Sammaritano; T J Blanck
Journal:  Thromb Haemost       Date:  2001-12       Impact factor: 5.249

7.  Antiphospholipid antibodies associated with alcoholic liver disease specifically recognise oxidised phospholipids.

Authors:  R Rolla; D Vay; E Mottaran; M Parodi; M Vidali; M Sartori; C Rigamonti; G Bellomo; E Albano
Journal:  Gut       Date:  2001-12       Impact factor: 23.059

8.  A simple method to discriminate between beta2-glycoprotein I- and prothrombin-dependent lupus anticoagulants.

Authors:  M J A Simmelink; R H W M Derksen; J Arnout; P G De Groot
Journal:  J Thromb Haemost       Date:  2003-04       Impact factor: 5.824

Review 9.  CNS dysfunction in the antiphospholipid syndrome.

Authors:  A Katzav; J Chapman; Y Shoenfeld
Journal:  Lupus       Date:  2003       Impact factor: 2.911

10.  Moderate alcohol consumption increases oxidative stress in patients with chronic hepatitis C.

Authors:  Cristina Rigamonti; Elisa Mottaran; Emanuela Reale; Roberta Rolla; Valentina Cipriani; Francesca Capelli; Renzo Boldorini; Matteo Vidali; Massimo Sartori; Emanuele Albano
Journal:  Hepatology       Date:  2003-07       Impact factor: 17.425

View more
  2 in total

1.  Novel Autoimmune IgM Antibody Attenuates Atherosclerosis in IgM Deficient Low-Fat Diet-Fed, but Not Western Diet-Fed Apoe-/- Mice.

Authors:  Olga A Cherepanova; Prasad Srikakulapu; Elizabeth S Greene; Malay Chaklader; Ryan M Haskins; Mary E McCanna; Smarajit Bandyopadhyay; Bhupal Ban; Norbert Leitinger; Coleen A McNamara; Gary K Owens
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-10-24       Impact factor: 8.311

2.  Phospholipid-esterified eicosanoids are generated in agonist-activated human platelets and enhance tissue factor-dependent thrombin generation.

Authors:  Christopher P Thomas; Lloyd T Morgan; Benjamin H Maskrey; Robert C Murphy; Hartmut Kühn; Stanley L Hazen; Alison H Goodall; Hassan A Hamali; Peter W Collins; Valerie B O'Donnell
Journal:  J Biol Chem       Date:  2010-01-08       Impact factor: 5.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.